@entity550 for trigeminal neuropathic or deafferentation XXXX : an institutional case series experience.

@entity1 @entity550 @entity16 @entity158 @entity9
BACKGROUND: Trigeminal @entity16 is a rare, devastating condition that can be intractable and resistant to treatment. When medical treatment fails, invasive options are limited. @entity550 ( @entity550 ) is a relatively recent technique introduced to treat central @entity9 . The use of @entity550 to treat trigeminal neuropathic or deafferentation @entity158 is not widespread and clinical data in the medical literature that demonstrate efficacy are limited. METHOD: We retrospectively reviewed @entity1 with trigeminal neuropathic or trigeminal deafferentation @entity158 who were treated at the Oregon Health _ Science University between 2001 and 2008 by 1 neurosurgeon using @entity550 . RESULTS: Eight of 11 @entity1 (3 male, 8 female) underwent successful permanent implantation of an @entity550 system. All 8 @entity1 reported initial @entity158 control. Three failed to experience continued @entity158 control (6 months of follow-up). Five continued to experience long-term @entity158 control (mean follow-up, 33 months). Average programming sessions were 2.2/year (all 8 @entity1 ) and 1.55/year (5 @entity1 who sustained long-term @entity158 control). @entity1 with anesthesia dolorosa or trigeminal deafferentation @entity158 who had previously undergone ablative trigeminal procedures responded poorly to @entity550 . We encountered no perioperative complications. CONCLUSION: @entity550 is a safe and potentially effective therapy in certain @entity1 with @entity16 .
